MGTX

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Graviton BioScience announced publication of positive Phase 1b results for GV101 in chronic graft-versus-host diseaseAug 26, 2026
• Graviton BioScience received FDA clearance for the IND application for GV101 to treat Friedreich's ataxiaAug 11, 2026
• MeiraGTx announced it will present 3-year data from its Phase 1 AQUAx gene therapy study for xerostomiaApr 14, 2026
• MeiraGTx received FDA Breakthrough Therapy designation for AAV2-hAQP1 in radiation-induced xerostomiaMar 26, 2026
• MeiraGTx enters into strategic collaboration with Eli Lilly and Company to develop and commercialize genetic medicines in ophthalmologyNov 10, 2025